利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

113 条记录 (耗时 0.055 秒)

    Methods of preventing and reducing the severity of stress-associated conditions
    18.
    发明授权
    Methods of preventing and reducing the severity of stress-associated conditions 有权
    预防和减轻压力相关病症严重程度的方法

    公开(公告)号：US07977335B2

    公开(公告)日：2011-07-12

    申请号：US12114727

    申请日：2008-05-02

    申请人： Daniel W. Gil ,  Scott Whitcup ,  Mitchell F. Brin ,  John E. Donello

    发明人： Daniel W. Gil ,  Scott Whitcup ,  Mitchell F. Brin ,  John E. Donello

    IPC分类号： A61K31/198

    CPC分类号： A61K31/498

    摘要： The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.

    摘要翻译： 本发明提供了通过向受试者全身施用有效量的溴莫尼定或其药学上可接受的盐，酯，酰胺，立体异构体或外消旋混合物来提供预防或减轻受试者的应激相关状况的严重性的方法。 可以根据本发明的方法治疗的应激相关病症包括但不限于消化不良，与心肌缺血相关的心动过速以外的心动过速，惊恐发作，非炎性皮肤病学条件，肌肉收缩障碍，感觉超敏反应 与偏头痛和行为障碍相关。

    NONSEDATING ALPHA-2 AGONISTS
    19.
    发明申请
    NONSEDATING ALPHA-2 AGONISTS 有权
    不吸烟的ALPHA-2激动剂

    公开(公告)号：US20110034525A1

    公开(公告)日：2011-02-10

    申请号：US12878593

    申请日：2010-09-09

    申请人： Ken Chow ,  Todd M. Heidelbaugh ,  John E. Donello ,  Daniel W. Gil

    发明人： Ken Chow ,  Todd M. Heidelbaugh ,  John E. Donello ,  Daniel W. Gil

    IPC分类号： A61K31/4164 ,  A61P1/08 ,  A61P25/00 ,  A61P25/06

    CPC分类号： A61K31/4164 ,  C07D233/84

    摘要： The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. The present invention further provides a pharmaceutical composition that contains a pharmaceutical carrier and a therapeutically effective amount of an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof.

    摘要翻译： 本发明提供一种α-2A /α-1A选择性激动剂，其包括由结构1表示的化合物或其药学上可接受的盐，酯，酰胺，消旋异构体或外消旋混合物。 本发明还提供了含有药物载体和治疗有效量的α-2A /α-1A选择性激动剂的药物组合物，其包括由结构1表示的化合物或其药学上可接受的盐，酯，酰胺，消旋异构体或外消旋 的混合物。